Literature DB >> 30690197

Adverse drug reactions on sexual functioning: a systematic overview.

Rineke Gordijn1, Martina Teichert2, Melianthe P J Nicolai3, Henk W Elzevier4, Henk-Jan Guchelaar2.   

Abstract

Adverse drug reactions (ADRs) that diminish sexual functioning can seriously affect a person's quality of life and can also affect drug adherence. However, no comprehensive overview on the subject is available and a lack of knowledge among healthcare professionals might be present. This systematic review of Summary of Products Characteristics identified 346 drugs registered with at least one sexual ADR. The drug class 'nervous system' (N) was represented most frequently with 105 drugs, followed by 'cardiovascular system' (C) with 89 drugs. For 16 drugs an incidence rate for sexual ADR of >10% was reported and for 98 drugs there was an incidence rate >1%. Because sexual ADRs occur in frequently used drugs, they should be considered in clinical practice to optimize drug treatment.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30690197     DOI: 10.1016/j.drudis.2019.01.012

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  3 in total

1.  Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database.

Authors:  Carolina Valeiro; Cristiano Matos; Joep Scholl; Florence van Hunsel
Journal:  Drug Saf       Date:  2022-04-07       Impact factor: 5.606

2.  Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.

Authors:  Henry Zakumumpa; Ronald Kiguba; Helen Byomire Ndagije; Gilbert Ategeka; Jacquellyn Nambi Ssanyu; Freddy Eric Kitutu
Journal:  BMC Infect Dis       Date:  2022-08-15       Impact factor: 3.667

3.  An estimation of patients at potential risk for drug-induced sexual dysfunction using pharmacy dispensing data.

Authors:  Rineke Gordijn; Melianthe P J Nicolai; Henk W Elzevier; Henk-Jan Guchelaar; Martina Teichert
Journal:  Fam Pract       Date:  2021-06-17       Impact factor: 2.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.